摘要
目的探讨低分子肝素钙联合奥拉西坦对血管性认知功能障碍的效果。方法 100例血管性认知障碍患者随机分为对照组32例,奥拉西坦组34例,联合组34例,对照组给予常规治疗+安慰剂治疗,奥拉西坦组在常规治疗的基础上,给予奥拉西坦,联合组在常规治疗的基础上,给予奥拉西坦与低分子肝素钙,疗程为2个月。运用简易智力状态检查量表(MMSE)和日常生活能力量表(ADL)评价效果。结果 2个月后联合组MMSE和ADL评分值提高(P<0.01)。结论低分子肝素钙联合奥拉西坦可以显著改善血管性认知障碍患者的认知功能。
Objective To investigate the clinical effects of combination therapy with low molecular weight heparin calcium（LMWHC） and oxiracetam for the patients with vascular cognitive impairment（VCI）.Methods One hundred patients who were diagnosed with VCI were randomly divided into LMWHC combined with oxiracetam group（the combination group,34cases）,the oxiracetam group（34cases） and placebo group（the control group,32cases）.All cases received routine medication.The efficacy was evaluated by using mini-mental state examination（MMSE） and activities of daily living（ADL） before and after treatment of 2 months.Results There were significant improvements of MMSE and ADL total scores in the oxiracetam group and the combination group after treatment（P0.01）.Compared with control group,Significant difference（P0.05） was seen in the other two groups.Significant difference was also seen between combination group and oxiracetam group（P=0.035）.Conclusions The combination therapy with LMWHC and oxiracetam has positive effect for patients with VCI.
出处
《社区医学杂志》
2012年第20期7-9,共3页
Journal Of Community Medicine
